STATEN ISLAND, N.Y. — The U.S. Food and Drug Administration (FDA) has announced a recall of 89,312 bottles of a popular nasal ...
Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.
Almost 100,000 bottles of nasal spray were recalled for a "microbial failure" that led to multiple complaints from customers.
The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...
Resyca® specialises in the development and manufacturing of compact, user-friendly soft mist inhalation and soft nasal spray devices, incorporating the proprietary Medspray micro-nozzle technology.
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.